Oragenics, Inc. (OGEN) Stock: Why It’s Down


Oragenics, Inc. (OGEN) is making a move down in the market today. The stock, focused in the biotech space, is currently priced at $0.61 after heading down -30.29% so far in today’s session. In terms of biotech companies, there are a number of aspects that have the ability to generate declines in the market. News is one of the most common reasons for movement. Here are the most recent trending headlines centered around OGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-21-19 06:00AM Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering
Mar-20-19 05:16PM 6 Stocks Moving In Wednesday’s After-Hours Session
04:40PM Organics Announces Proposed Underwritten Public Offering
Mar-18-19 02:00PM Four Healthcare Stocks Heating Up On Monday
Mar-15-19 04:17PM Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial

Nonetheless, when making a decision with regard to investing, investors should look at far more than just news, this is especially the case in the speculative biotechnology space. Here’s what’s happening with Oragenics, Inc..

Recent Movement Out of OGEN

Although a move down on a single session, like the fall that we’re seeing from Oragenics, Inc. might make some investors tremble, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s generally a good idea to look into trends further out than a single trading session. When it comes to OGEN, here are the trends that investors have seen:

  • Past Seven Days – In the last five trading sessions, OGEN has seen a price change that amounts to -31.37%.
  • Past 30 Days – The return from Oragenics, Inc. over the past 30 days has been -32.22%.
  • Quarterly – Throughout the past 3 months, the stock has generated a ROI that works out to -29.13%
  • Past 6 Months – Throughout the previous six months, investors have seen a performance that works out to 46.92% from the stock.
  • Year To Date – Since the close of last year OGEN has resulted in a return of -28.97%.
  • Annually – Finally, throughout the past year, investors have seen a change that works out to -69.19% out of OGEN. Over this period, the stock has sold at a high price of -83.69% and a low of 60.53%.

Ratios To Pay Attention To

Looking at a few key ratios having to do with a company generally gives traders a view of how risky and/or rewarding a pick might be. Here are some of the key ratios to look at when digging into OGEN.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors are expecting that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks can have a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, as it relates to Oragenics, Inc., it’s short ratio amounts to 1.18.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure whether or not a company can pay for its debts as they mature using current assets or quick assets. Because many biotech many companies are heavily reliant on the continuation of support from investors, these ratios can be damning. However, quite a few better companies in the biotechnology industry do have strong quick and current ratios. In terms of OGEN, the quick and current ratios come to 9.90 and 9.90 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio works out to 0.60.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Several clinical stage biotech companies have a hard time keeping cash on hand. So, if you’re interested in a biotech stock, this is an important ratio to consider. In terms of OGEN, the cash to share value is 0.47.

How Analysts Feel About Oragenics, Inc.

Although it’s not a smart idea to blindly follow the opinions of analysts, it is a smart idea to consider their thoughts in order to validate your own opinions when it comes to making an investment decision in the biotech space. Here are the most recent moves that we’ve seen from analysts when it comes to OGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Big Money And Oragenics, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in OGEN, here’s what we’re seeing:

Institutions own 11.30% of the company. Institutional interest has moved by -13.74% over the past three months. When it comes to insiders, those who are close to the company currently own 6.89% percent of OGEN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

Looking At Share Counts

Traders seem to be interested in the counts of shares both outstanding and available. In terms of Oragenics, Inc., there are currently 29.44M with a float of 27.41M. These numbers mean that out of the total of 29.44M shares of OGEN currently in existence today, 27.41M are available to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to OGEN, the short percent of the float is 6.06%.

What We’ve Seen In earnings results

What have ween seen from OGEN in terms of financial results?Here’s what you need to know:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that Oragenics, Inc. will come up with EPS coming to a total of -0.28, with -0.10 being announced in the next financial report. Although this information is not associated with earnings, since we are talking on the topic of Wall Street analysts, OGEN is currently rated a 0 on a scale from 1 to 5 where 1 is the poorest Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – Throughout the past 5 years, Oragenics, Inc. has announced a movement in sales that works out to be 0. EPS in the last 5 years have generated a change of 21.70%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is often represented in today’s society, Oragenics, Inc. has created a change in earnings that comes to a total of 16.70%. Oragenics, Inc. has also experienced movement when it comes to sales volume that amounts to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, based on what I am, I can learn by myself. However, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social media trends and other publicly available data, but I am able to learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at data? If so, leave a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here